

S4 Table. Studies targeted for the analysis but not included

First Author	Treatment arms	Sites	Region	Country	Enrolled	Follow up (days)	Randomised	Recruitment period	Treatment arms	Pv patients enrolled	Pv treated with AL or DP	Female (%)	Age		Reason not included
													Mean (SD)	Median (range)	
Krudsood-2007 [212]	2	1	Asia-Pacific	Thailand	98	28	Yes	2004-2005	AL; CQ	98	47	25.5	25.1 (6.9)	- (15-65)	No response from investigators
Yohannes-2011 [213]	2	2	Africa	Ethiopia	159	28	No	2004-2005	AL; CQ	159	88	55.7	Not stated	17 (9.5-24)	No response from investigators
Tjitra-2012 [214]	2	2	Asia-Pacific	Indonesia	401	42	Yes	2007-2008	DP; Art+N	248	126	15.0	26.2 (9.2)	- (15-67)	No response from investigators
Eibach-2012 [208]	1	2	The Americas	Guyana	74	28	No	2009-2010	AL+PQ	74	74	9.5	Not stated	24 (5-57)	Investigator contact details unavailable
Senn-2013 [209]	1	1	Asia-Pacific	Papua New Guinea	926	42	No	2006-2010	AL	594	594	Not stated	Not stated	Not stated	Initial investigator response but no data provided
Leang-2013 [210]	1	4	Asia-Pacific	Cambodia	828	28	No	2008-2011	DP; CQ	390	173	28.3	22.9 (-)	- (3-60)	Initial investigator response but no data provided
Lon-2014 [211] ^a	1	2	Asia-Pacific	Cambodia	80	180	Yes	2010-2011	DP; DP	65	65	3.8	33.8 (-)	Not stated	Initial investigator response but no data provided
Shaikh-2017 [215]	1	1	Asia-Pacific	Pakistan	109	42	No	2012-2013	DP±PQ	109	109	39.0	Not stated	- (1-15)	No response from investigators

Pv – *P. vivax*; SD – standard deviation; AL – artemether-lumefantrine; CQ – chloroquine; DP – dihydroartemisinin-piperaquine; ART - artemisinin; N - naphthoquine; PQ – primaquine

^a Sex and age estimates include 15 patients with *P. falciparum*.